相关实验视频

Updated: Jun 13, 2025

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

转移性尿癌的新进展:关于最近的发展和未来前景的叙述性审查

Elena Tonni¹, Marco Oltrecolli¹, Marta Pirola¹

¹Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.

International journal of molecular sciences

|September 14, 2024

概括

新的抗体 - 药物结合物 (ADC) 显示出治疗晚期泌尿腺癌的前景. 这些药物代表了重大进展,为转移性疾病患者提供了新的希望.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

转移性尿路细胞癌 (mUC) 治疗历史上依赖基化疗.
最近的进展包括针对特定遗传变化的免疫检查点抑制剂和纤维细胞生长因子受体 (FGFR) 抑制剂.

研究的目的:

审查不断变化的mUC治疗选择格局.
提供对新型疗法的分子基础和机制的见解.
评估针对个性化治疗方法的新疗法策略.

主要方法:

对mUC的现有和新兴治疗方法的文献综述.
对新药物分子点和作用机制的分析.
评估临床试验数据和监管批准.

主要成果:

抗体-药物合物 (ADCs) 已成为对mUC的有前途的新疗法.
恩福图马布维多丁和萨基图祖马布戈维特康是加速批准的领先的ADC.
许多其他ADC正在调查中,这表明正在进行大量的研究.

结论:

ADCs代表了显著的进步和mUC治疗的"新前沿".
这些药物有可能改变未来的转移性尿路细胞癌的治疗方法.
个性化治疗策略在mUC治疗中变得越来越重要.

关键词:

在FGFR中,FGFR是FGFR.在HER2中,HER2是HER2.抗体药物合物抗体药物合物恩福图马布 (enfortumab) 是一种可见的药物.赫达菲提尼布 (herdafitinib) 是一种药物.免疫检查点抑制剂免疫检查点抑制剂萨基图祖马布 (Sacituzumab) govitecan可以使用.泌尿器癌泌尿器癌

更多相关视频

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

相关概念视频

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...